News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Cells derived from iPSC can be immunogenic - Yes or No?
|Title||Cells derived from iPSC can be immunogenic - Yes or No?|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Cao J, Li X, Lu X, Zhang C, Yu H, Zhao T|
|Journal||Protein & cell|
|Date Published||2013 Sep 3|
The induced pluripotent stem cells (iPSCs), derived by ectopic expression of reprogramming factors in somatic cells, can potentially provide unlimited autologous cells for regenerative medicine. In theory, the autologous cells derived from patient iPSCs should be immune tolerant by the host without any immune rejections. However, our recent studies have found that even syngeneic iPSC-derived cells can be immunogenic in syngeneic hosts by using a teratoma transplantation model (Zhao et al., 2011). Recently two research groups differentiated the iPSCs into different germ layers or cells, transplanted those cells to the syngeneic hosts, and evaluated the immunogenicity of those cells. Both of the two studies support our conclusions that some certain but not all tissues derived from iPSCs can be immunogenic, although they claimed either "negligible" or "lack of" immunogenicity in iPSC derivatives (Araki et al., 2013; Guha et al., 2013). To test the immunogenicity of clinically valuable cells differentiated from human iPSCs are emergently required for translation of iPSC technology to clinics.
|Alternate Journal||Protein Cell|